share_log

Medical Properties Trust Analyst Ratings

Benzinga ·  Nov 10, 2023 06:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/10/2023 -0.88% Stifel $12 → $4.5 Downgrades Buy → Hold
10/17/2023 -11.89% Wells Fargo $7 → $4 Maintains Underweight
10/16/2023 -11.89% Wells Fargo → $4 Downgrades Equal-Weight → Underweight
09/25/2023 120.26% RBC Capital → $10 Reiterates Outperform → Outperform
08/31/2023 98.24% Mizuho $18 → $9 Downgrades Buy → Neutral
08/22/2023 120.26% Barclays $12 → $10 Maintains Overweight
08/21/2023 54.19% JP Morgan $9 → $7 Downgrades Neutral → Underweight
08/14/2023 120.26% RBC Capital $12 → $10 Maintains Outperform
08/11/2023 76.21% B of A Securities $9 → $8 Downgrades Neutral → Underperform
08/11/2023 Raymond James Downgrades Strong Buy → Underperform
06/23/2023 120.26% Truist Securities $9 → $10 Maintains Hold
04/20/2023 98.24% Wells Fargo → $9 Initiates Coverage On → Equal-Weight
04/19/2023 98.24% Wells Fargo → $9 Initiates Coverage On → Equal-Weight
04/05/2023 164.32% Barclays $14 → $12 Maintains Overweight
04/04/2023 230.4% Keybanc $16 → $15 Maintains Overweight
03/31/2023 98.24% Truist Securities $8 → $9 Maintains Hold
03/29/2023 76.21% Truist Securities $14 → $8 Maintains Hold
03/16/2023 120.26% B of A Securities → $10 Downgrades Buy → Neutral
03/07/2023 142.29% Credit Suisse → $11 Reiterates → Neutral
03/03/2023 164.32% JP Morgan $14 → $12 Maintains Neutral
03/02/2023 252.42% Raymond James $18 → $16 Maintains Strong Buy
02/27/2023 208.37% Barclays $17 → $14 Maintains Overweight
02/24/2023 142.29% Credit Suisse $13 → $11 Maintains Neutral
01/27/2023 274.45% Barclays $19 → $17 Maintains Overweight
01/19/2023 252.42% Keybanc $18 → $16 Maintains Overweight
01/17/2023 186.34% Credit Suisse $11 → $13 Maintains Neutral
12/21/2022 142.29% Credit Suisse $17 → $11 Maintains Neutral
11/14/2022 252.42% B of A Securities → $16 Upgrades Neutral → Buy
10/21/2022 318.5% Barclays $23 → $19 Maintains Overweight
10/04/2022 296.48% RBC Capital $20 → $18 Maintains Outperform
09/22/2022 296.48% Raymond James $20 → $18 Maintains Strong Buy
09/16/2022 230.4% Deutsche Bank $17 → $15 Maintains Hold
08/04/2022 406.61% Barclays $27 → $23 Maintains Overweight
07/29/2022 340.53% Mizuho $26 → $20 Maintains Buy
07/15/2022 340.53% Raymond James $24 → $20 Maintains Strong Buy
07/14/2022 274.45% Credit Suisse $23 → $17 Downgrades Outperform → Neutral
07/13/2022 274.45% Deutsche Bank $20 → $17 Maintains Hold
07/07/2022 296.48% Keybanc $23 → $18 Maintains Overweight
06/30/2022 230.4% Jefferies $19 → $15 Maintains Hold
06/22/2022 296.48% JP Morgan $24 → $18 Downgrades Overweight → Neutral
05/20/2022 384.58% RBC Capital $25 → $22 Maintains Outperform
05/10/2022 428.63% Raymond James $26 → $24 Maintains Strong Buy
05/02/2022 406.61% Credit Suisse $26 → $23 Maintains Outperform
04/27/2022 340.53% Deutsche Bank $25 → $20 Maintains Hold
04/27/2022 406.61% Keybanc $24 → $23 Maintains Overweight
04/22/2022 340.53% Jefferies $25 → $20 Downgrades Buy → Hold
03/24/2022 406.61% Truist Securities $26 → $23 Maintains Hold
03/11/2022 B of A Securities Downgrades Buy → Neutral
02/14/2022 472.69% Credit Suisse $27 → $26 Maintains Outperform
02/01/2022 Credit Suisse Initiates Coverage On → Outperform
01/03/2022 450.66% Deutsche Bank $27 → $25 Downgrades Buy → Hold
10/29/2021 472.69% Raymond James $25 → $26 Maintains Strong Buy
10/27/2021 428.63% B of A Securities $21.5 → $24 Upgrades Neutral → Buy
10/26/2021 450.66% Raymond James → $25 Initiates Coverage On → Strong Buy
08/11/2021 406.61% RBC Capital → $23 Upgrades Sector Perform → Outperform
07/14/2021 406.61% Mizuho → $23 Assumes → Buy
07/06/2021 373.57% B of A Securities → $21.5 Downgrades Buy → Neutral
06/15/2021 406.61% Wolfe Research → $23 Initiates Coverage On → Peer Perform
05/03/2021 406.61% RBC Capital $24 → $23 Downgrades Outperform → Sector Perform
01/22/2021 384.58% Truist Securities → $22 Downgrades Buy → Hold
01/21/2021 428.63% KeyBanc $22 → $24 Maintains Overweight
12/15/2020 428.63% Deutsche Bank → $24 Upgrades Hold → Buy
09/02/2020 362.56% Stifel → $21 Reinstates → Buy
08/24/2020 406.61% Mizuho $20 → $23 Upgrades Neutral → Buy
07/10/2020 318.5% Deutsche Bank $23 → $19 Downgrades Buy → Hold
06/25/2020 340.53% SunTrust Robinson Humphrey $19 → $20 Maintains Buy
04/23/2020 318.5% SunTrust Robinson Humphrey $22 → $19 Maintains Buy
04/21/2020 340.53% Keybanc $25 → $20 Maintains Overweight
04/03/2020 252.42% Wells Fargo $21 → $16 Maintains Equal-Weight
04/03/2020 340.53% JP Morgan $25 → $20 Maintains Overweight
03/30/2020 318.5% Mizuho → $19 Downgrades Buy → Neutral
01/16/2020 406.61% Keybanc $22 → $23 Maintains Overweight
01/14/2020 384.58% Baird $20 → $22 Maintains Neutral
12/26/2019 472.69% Mizuho $25 → $26 Maintains Buy
12/20/2019 450.66% Mizuho → $25 Initiates Coverage On → Buy
10/14/2019 329.52% B of A Securities → $19.5 Initiates Coverage On → Neutral
09/12/2019 384.58% Berenberg → $22 Initiates Coverage On → Buy
09/03/2019 340.53% Barclays → $20 Initiates Coverage On → Overweight
08/27/2019 362.56% SunTrust Robinson Humphrey $20 → $21 Maintains Buy
08/07/2019 340.53% Keybanc → $20 Upgrades Sector Weight → Overweight
07/24/2019 318.5% Stifel $18 → $19 Upgrades Hold → Buy
07/02/2019 340.53% SunTrust Robinson Humphrey $19 → $20 Upgrades Hold → Buy
03/29/2019 252.42% Deutsche Bank $14 → $16 Maintains Hold
02/13/2019 406.61% Jefferies $18 → $23 Upgrades Hold → Buy
12/11/2018 285.46% Wells Fargo $13.5 → $17.5 Upgrades Underperform → Market Perform

What is the target price for Medical Properties Trust (MPW)?

The latest price target for Medical Properties Trust (NYSE: MPW) was reported by Stifel on November 10, 2023. The analyst firm set a price target for $4.50 expecting MPW to fall to within 12 months (a possible -0.88% downside). 28 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Medical Properties Trust (MPW)?

The latest analyst rating for Medical Properties Trust (NYSE: MPW) was provided by Stifel, and Medical Properties Trust downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Medical Properties Trust (MPW)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.

Is the Analyst Rating Medical Properties Trust (MPW) correct?

While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a downgraded with a price target of $12.00 to $4.50. The current price Medical Properties Trust (MPW) is trading at is $4.54, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment